Trial Profile
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Long QT syndrome
- Focus Therapeutic Use
- 19 Dec 2012 New trial record